MDxHealth SA MDXH

MDXH Company Overview

MDxHealth SA is a molecular diagnostics company focused on precision medicine solutions for urologic cancers, particularly prostate cancer. The company develops and commercializes genomic and epigenetic tests designed to support physicians in cancer detection, risk stratification, treatment selection, and disease monitoring. MDxHealth operates within the molecular diagnostics, oncology diagnostics, and precision health industries, serving healthcare providers, urology practices, hospitals, and laboratory networks primarily in the United States and Europe.

The company’s principal revenue drivers are its proprietary diagnostic assays, including Confirm mdx, Select mdx, GPS (Genomic Prostate Score), and Resolve mdx, which are used to help guide clinical decisions related to prostate cancer diagnosis and treatment planning. MDxHealth evolved through a combination of internal assay development and strategic acquisitions, most notably the acquisition of Genomic Health’s urology business from Exact Sciences in 2022, which expanded its commercial portfolio and strengthened its position in the urologic diagnostics market. The company positions itself as a specialized provider of clinically validated molecular tests integrated into urology workflows and supported by reimbursement relationships with U.S. payors.